The present invention relates to a vascular-hyperpermeability-inhibiting amount of a compound selected from danazol and pharmaceutically acceptable salts of danazol, for use in inhibiting vascular hyperpermeability in an animal in need thereof, wherein the vascular hyperpermeability is vascular hyperpermeability of a continuous endothelium or a fenestrated endothelium.